Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be c...

Descripción completa

Detalles Bibliográficos
Autores principales: Earhart, A.P., Holliday, Z.M., Hofmann, H.V., Schrum, A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192073/
https://www.ncbi.nlm.nih.gov/pubmed/32355564
http://dx.doi.org/10.1016/j.nmni.2020.100689
_version_ 1783527955473891328
author Earhart, A.P.
Holliday, Z.M.
Hofmann, H.V.
Schrum, A.G.
author_facet Earhart, A.P.
Holliday, Z.M.
Hofmann, H.V.
Schrum, A.G.
author_sort Earhart, A.P.
collection PubMed
description We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.
format Online
Article
Text
id pubmed-7192073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71920732020-04-30 Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome Earhart, A.P. Holliday, Z.M. Hofmann, H.V. Schrum, A.G. New Microbes New Infect Letter to the Editor We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19. Elsevier 2020-04-30 /pmc/articles/PMC7192073/ /pubmed/32355564 http://dx.doi.org/10.1016/j.nmni.2020.100689 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Earhart, A.P.
Holliday, Z.M.
Hofmann, H.V.
Schrum, A.G.
Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
title Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
title_full Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
title_fullStr Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
title_full_unstemmed Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
title_short Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
title_sort consideration of dornase alfa for the treatment of severe covid-19 acute respiratory distress syndrome
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192073/
https://www.ncbi.nlm.nih.gov/pubmed/32355564
http://dx.doi.org/10.1016/j.nmni.2020.100689
work_keys_str_mv AT earhartap considerationofdornasealfaforthetreatmentofseverecovid19acuterespiratorydistresssyndrome
AT hollidayzm considerationofdornasealfaforthetreatmentofseverecovid19acuterespiratorydistresssyndrome
AT hofmannhv considerationofdornasealfaforthetreatmentofseverecovid19acuterespiratorydistresssyndrome
AT schrumag considerationofdornasealfaforthetreatmentofseverecovid19acuterespiratorydistresssyndrome

Ejemplares similares